Glenmark was one of a number of drugmakers that have decided to build US manufacturing plants due to FDA restrictions on facilities in India that was keeping them from exporting to the US. Glenbrook, a Mumbai-based generics company plans to open its $100 million plant today in North Carolina.
The dynamic 100,000 square foot building is designed to produce not only a variety of fixed dose formulations in tablets and capsules but also vials and prefilled syringes as well as ampoules for inhaled formulations. The company expects to build employment there well beyond the 168 workers currently on site.
Click here to view the entire article.